Precision medicine for cardiovascular disease – time to act

PlaqueTec
Oct 7
1 min read

Published in European Biopharmaceutical Review, Dr Simon Williams, General Manager at PlaqueTec, explores the global impact of coronary artery disease (CAD), the largest contributor to cardiovascular diseases. CAD is a more complex heterogeneous condition than originally thought, with varied clinical presentation and numerous genetic associations. Despite this, treatment approaches largely focus on broad risk factor optimisation, rather than patient and disease-specific treatments. In this article Simon asserts action is needed to address this and discusses:

The role of inflammation in CAD progression
Defining disease endotypes among the vast CAD population
Enabling a precision medicine approach to treatment and the potential impact this could have

READ THE ARTICLE HERE